← All trials
NCT06308263
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2024
- Primary completion
- Nov 26, 2025
- Completion date
- Nov 26, 2025
- First posted
- Mar 13, 2024
- Last posted
- Jul 23, 2024
- Enrollment
- 6
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Merck KGaALead sponsor
- Merck KGaAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.